Prevenar vaccine ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-006539-29-SE (EUCTR) | 14/03/2008 | 20/12/2007 | Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar | Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar | Patients with rheumatic diseases (rheumatoid arthritis and spondyloarthripaties) who are going to be vaccinated with Prevenar vaccine in order to study the serological responses to two pneumococcal serotypes and to study the impact of different treatment modalities on serological responses. | Trade Name: Prevenar vaccine Product Name: Prevenar vaccine INN or Proposed INN: 7-valent Pneumococcal Conjugate vaccine | Dept of Rheumatology, Lund University Hospital, Lund, Sweden | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Sweden |